- ADJUNCT ASSOCIATE PROFESSOR Preventive Medicine
PharmD., University of Southern California
B.S., University of Maryland
University of California at San Francisco
- Dr. Arnold's clinical interests include:
Pediatric and adult asthma
Human Papillomavirus Vaccine
Real-world application of pharmacoeconomic principles
Interactive software in medical decision-making
Outcomes research in asthma, dermatology, cardiovascular medicine, HPV vaccines, pediatrics
Arnold R. Introduction to Pharmacoeconomics...from theory to practice (in press). Boca Raton, Taylor and Francis Group, LLC;.
Arnold RG, Kuan RK. Quality of life and costs in atopic dermatitis. In: Preedy VR, Watson RR, editors. Handbook of Disease Burdens and Quality of Life Measures (2008). Heidelberg, Springer;.
Marcus P, Arnold RG, Ekins S, Et Al. . A Retrospective Randomized Study of Asthma Control in the US: Results of the CHARIOT Study. Current Medical Research and Opinion 2008; 24: 3443-3452.
Cheng JM, Arnold RG. Pharmacoeconomic Review of Medical Management of Persistent Asthma. Allergy and Asthma Proceedings 2008 March-April; 29(2).
Arnold RG. Cost-Effectiveness Analysis: Should It Be Required for Drug Registration and Beyond?. Drug Discov Today 2007; 12/21-22: 960-965.
Arnold RG, Donnelly A, Altieri L, Wong KS, Sung J. Assessment of outcomes and parental impact on quality of life endpoints in the management of atopic dermatitis (ATOPIQUE). Managed Care Interface 2007; 20: 18-23.
Arnold R. Use of interactive software in medical decision making. In: Ekins S, editor. Computer Applications in Pharmaceutical Research and Development (2006). Hoboken, John Wiley & Sons, Inc.;.
Arnold RG, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. Cardiol Rev 2006; 14: 7-13.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Arnold did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Arnold Consultancy & Technology LLC
5 Penn Plaza, 19th Floor
New York, NY 10001